Mark T. Hurt, Abingdon, VA, and Paul W. Roop, II, Beckley, WV, for Mark Radcliffe. Counsel also stated that on July 28, 2005, she spoke to an attorney from the Department of Justice who expressed an interest in using electronic searches to identify documents [Redacted]. Because MS Contin and OxyContin were designed for chronic dosing, these physicians believed the 1:1 equianalgesic ratio was the appropriate one. Relators claims had no objectively reasonable chance of success, the company argues. He also refers to, but does not cite, a single-dose study supporting the 2:1 ratio that he was told about by his supervisors at Purdue. Green, 59 F.3d at 956. The FCA provides that there is no subject matter jurisdiction in a case where the claim is. This subsection includes disclosures made in "criminal hearings," as well as those made in "administrative investigations," but I cannot see that, nor have the parties asserted that, either of these classifications applies to the current situation. Curtis et al., Relative Potency of Controlled-Release Oxycodone and Controlled-Release Morphine in Postoperative Pain Model, 55 Eur. They amended their complaint, and again Purdue Pharma asked Berger to dismiss it. That agency investigated and concluded that it could not substantiate the allegations. However, it is also clear from the evidence that the government continued to seek such information after the release had been executed on August 1, 2005. 2010), the district court dismissed . Beginning in 2002 and continuing for the next several years, the government sought millions of documents from Purdue and conducted hundreds of interviews, some of which pertained to the relative potency and cost of OxyContin and MS Contin. Despite the labeling of the 2001 page, I find that this is not analogous to a traditional news outlet or periodical or even a trade journal because it involves information disseminated by one company about its own products, rather than a news organization or industry group disseminating information of general or specialized interest. The generalized interest in settling litigation is outweighed in the present circumstances by public interests that would be impaired by enforcement of this release, and so analysis under the Rumery test does not favor enforcing Radcliffe's release. Purdue objects, but I find no cognizable basis for denying Radcliffe's request. Purdue next argues that other scientific publications supporting an equianalgesic ratio of 2:1, not only for single or intermittent dosing but also for longer-term use, are public disclosures because "[a]s a Purdue sales representative and supervisor, Radcliffe would have been trained on and intimately familiar with many Purdue articles endorsing a 2:1 equianalgesic potency ratio." In this case, that information was the first FCA suit filed by Mark Radcliffe. F. Brian Ferguson. at 818. Evidence presented in Bahrani demonstrated that, prior to executing a general release, the relator had two brief conversations with an FBI agent prior in which he made charges against his employer but offered no specifics regarding the alleged fraud. Defs.' 1999). Because a relator is only entitled to a portion of the proceeds from a successful qui tam suit, both the relator and the party accused of fraud could benefit financially by settling before the government learns of the allegations. decision in United States ex rel. All reasonable inferences are "viewed in the light most favorable to the party opposing the motion." Radcliff is a former sales representative and manager at Purdue, who left its employment shortly before he filed the present suit. Auth. It has been noted that "[c]ourts have applied Rumery to a broad spectrum of pre- and post-filing releases of qui tam claims entered into without the United States' knowledge or consent." Va. 2008). Id. (f)(2).) Further, because parties engaged in the fraud would be able to settle their claims with potential relators for significantly less than they would once the government became aware of the allegations, the FCA's deterrent effect is also lessened. 104 F.3d at 231. Radcliffe was a district sales manager for Purdue, laid off as part of a reduction in force in June 2005. Virginia, Abingdon Division, declining to conclude that anything posted online would automaticallyconstitute a public disclosure. Radcliffe was interviewed a second time in September 2006 and asked about the misleading promotion of OxyContin. Mot. For convenience, references herein to the "Complaint" shall include the most recent version. Rost v. Pfizer, Inc., 507 F.3d 720, 733 (1st Cir. (Information 20, United States v. Purdue Frederick Co., supra.) and as a result, generally more expensive than the OxyContin that was described in [Purdue's] marketing pitch to the same physicians." A separate order will be entered herewith. . 2548, 91 L.Ed.2d 265 (1986). See Fed.R.Civ.P. To the extent that Radcliffe based the allegations in his Complaint on either the published abstract or the published article, these constitute public disclosures in the news media. On June 24, 2005, a conversation took place between Department of Justice attorney Barbara Wells and attorney Michael Scheininger, who represented several Purdue employees, about topics that would be discussed when those employees testified before the grand jury investigating Purdue. Indus. (Mem. Mot. On Nov. 17, the company moved to have the plaintiffs pay its legal fees under the fee-shifting provisions in the FCA. It was dismissed for failure. He submits that each OxyContin prescription submitted to the government for reimbursement constitutes a false claim under the FCA and the analogous state statutes, because the product distributed had only half the potency that physicians and decision-makers had been led to believe it possessed. It is unclear from Hall whether the NRC was made aware of the identity of the specific person making the allegations when it first investigated the matter. Ten years ago, Mark Radcliffe, a former district sales manager for Purdue Pharma, filed a qui tam action under the FCA against Purdue. The two are represented by the same two attorneys who represented Mark Hurt and Roop. DEFENDANTS PATTY CARNES, MARK ROSS, MARK RADCLIFFE, GOODWIN DRUG COMPANY, AND CARL HOOKER Upon Consideration of the Plaintiffs' Motion for Stay (Transaction ID 64331563), this . One of their attorneys is Mark Id. Notwithstanding the government's lack of knowledge of or consent to the release, because the federal government was already aware of the allegations of fraud, the public interest in having information disclosed to the government was not implicated. Yannacopolous v. General Dynamics, 315 F. Supp. He alleges that this was done to induce physicians to prescribe OxyContin and other decision-makers to purchase or authorize the purchase of OxyContin. Mark Radcliffe, a former sales representative and district manager, filed the first related FCA lawsuit against Purdue Pharma in 2005 in Virginia federal court. 56(e)). 582 F. Supp. In addition to ruling the whistleblowers failed to sufficiently plead their allegations, Berger also found that their suit was barred by a rule that says whistleblowers cant bring suit over information that has already been made public. at 963-64. Id. Id. In his Complaint, Radcliffe cites the three publications shown to him by the physicians the Clinical Practice Guideline, the USP, and the Textbook of Pain to support the correctness of the 1:1 ratio. Several of these physicians directed Radcliffe to specific sources in the scientific literature to show that the correct equianalgesic ratio between MS Contin and OxyContin was closer to 1:1, meaning that OxyContin was less potent and more expensive than Purdue claimed. These terms included those related to the issues of relative potency and cost, as well as those that seem more related to the potential for abuse or the effects of withdrawal. at 960. Prior public disclosures revealed the spin off, the company's problems with the unfunded pension liability, and eventually, the company's bankruptcy. This case stemmed from a qui tam action under the FCA that Mark Radcliffe ("Radcliffe"), a former district sales manager for Purdue Pharma ("Purdue"), filed against Purdue, alleging that Purdue improperly labeled the drug OxyContin as having a higher pain . Coleson, which was decided prior to Green but after Rumery, involved a claim brought under the anti-retaliation provisions of the FCA, rather than a qui tam claim brought on behalf of the government. and, accordingly, less expensive than MSContin" and the accuracy of "the 2:1 comparison of OxyContin to MSContin." Id. Relators, or private individuals who bring suits on behalf of the government, are entitled to a portion of the recovery from a qui tam suit, the amount of which depends on whether the government chooses to intervene after learning the allegations and prosecute the case itself and the overall importance of the relator's participation in the action. Ga. Oct. 27, 2005) (citing DeCarlo for the opposite conclusion). Id. United States ex rel. In summary, Purdue argues that the public disclosures in these scientific articles and in the OxyContin package insert amount to a disclosure of the fraudulent transactions alleged in Radcliffe's qui tam suit and put the government on notice of the potential fraud. The parties have been provided with the sealed copy. Purdue argues that Radcliffe was a bad actor who waited to file his qui tam complaint and, prior to doing so, attempted to settle with Purdue in exchange for an investment in a company he was starting. Id. ( Id. Radcliffe's allegations pertain to the issue of the relative cost and potency of OxyContin and MS Contin. Purdue argues that in the present case, the following constitute public disclosures: (1) published scientific articles and reference materials cited in the Complaint, which support an equianalgesic ratio of 1:1 between MS Contin and OxyContin for repeated dosing, but note the existence of single-dose studies that support a ratio of 2:1; (2) a single-dose study that supports an equianalgesic ratio of 2:1 and a published article and an abstract reporting the results of this study; (3) other materials published in scientific journals, which support the 2:1 equianalgesic ratio for longer-term use, that Purdue argues Radcliffe would have been familiar with in his employment; and (4) the OxyContin package insert, which was approved by the FDA and was, at one time, available on Purdue's web site. 1990)). Defs.' The government's investigation continued and on December 5, 2005, AUSA Mountcastle moved to stay Radcliffe's qui tam suit pending the government's ongoing investigation. Several months later, Purdue restructured its sales force and Radcliffe was offered the option of transferring positions, which he declined, or termination with an extended severance package. Instead of the 2:1 ratio Purdue Pharma claimed, the actual ratio was more like 1.5:1, the whistleblowers said. Enforcing a release in this situation would deprive the public of a potential relator to enforce the FCA and recover monies for the government treasury. 2005); see Springfield, 14 F.3d at 655. The package insert recommends a starting conversion rate between OxyContin and MS Contin of 2:1, which can be reassessed based on a patient's reaction to the dosage. To determine whether the circumstances of a case fall within the general rule articulated in Green or the exception in Hall, the critical issue is the completeness of the government's knowledge or the fullness of its investigation. 2d at 1272. United States ex rel. Id. at 733-34 (remanding to allow leave to amend). Purdue moved to dismiss the Relators' complaint on res judicata grounds, arguing that our decision in Radcliffe barred . United States ex rel. regarding the relative potency of oxycodone." Had the substance of the relator's allegations been disclosed to an appropriate employee at the FDA with the authority to investigate these claims, that might have constituted a disclosure in an administrative investigation. See DeCarlo, 937 F. Supp. On August 1, 2005, Radcliffe executed a general release as part of . at 1047. However, the decision to enforce the release turned on the fact that the release occurred "in the context of a bankruptcy proceeding, not through a general, independent release of a claim for money." See United States v. Purdue Frederick Co., 495 F. Supp. The three articles cited by Radcliffe were published in scientific and medical reference periodicals that distribute new or updated material on a periodic basis. 425, 428 (1999). at 916. It has held that public policy is implicated only where "it is explicit, well defined and dominant, and ascertainable by reference to the laws and legal precedents and not from general considerations of supposed public interests." : 18-C-222 MSH, 18-C-233 MSH, 18-C-234 In his employment with Purdue between 1996 and 2005, Radcliffe was responsible for marketing OxyContin to individual physicians and became familiar with Purdue's marketing claims about OxyContin's relative cost and potency, including the claim that there is a 2:1 equianelgesic ratio between OxyContin and MS Contin. While the court reasoned that the enforceability of the release should be governed by federal law because it arose under federal law, the court did not address any of the public policy concerns associated with qui tam suits or the FCA. App. See Robert F. Kaiko et al., Analgesic Onset and Potency of Oral Controlled-Release (CR) Oxycodone and CR Morphine, 59(2) Clin. Id. Purdue's response was ambiguous, first stating that Radcliffe did not have legitimate claim, but if he thought he did he should make it, then expressing an interest in investing in Radcliffe's company. CV202-189, 2005 WL 3741538, at *5 (S.D. C2 (Feb. 1992) ("Clinical Practice Guideline"); United States Pharmacopeia-Dispensing Information 2238 tbl. 1039, 1043-47 (S.D.N.Y. First, was there a public disclosure? Likewise, the public interest in using qui tam suits to supplement federal enforcement of the FCA was not disturbed as the government had already investigated the allegations prior to the release. United States ex rel. at 966. 31 U.S.C.A. These employees were indeed asked questions pertaining to the relative potency issue during their grand jury appearances on July 20, 2005. C D.) In addition to its inclusion in OxyContin packages, the package insert is available on Purdue's publically-assessable web site. Attorneys who represented Mark Hurt and Roop OxyContin to MSContin. automaticallyconstitute a public disclosure ). To prescribe OxyContin and MS Contin and OxyContin were designed for chronic dosing, physicians. Left its employment shortly before he filed the present suit on Nov.,. United States v. Purdue Frederick Co., 495 F. Supp filed the present suit in Radcliffe barred dismiss.. The plaintiffs pay its legal fees under the fee-shifting provisions in the FCA Model, 55 Eur parties have provided... Not substantiate the allegations 2005 WL 3741538, at * 5 ( S.D two are represented by the same attorneys. 'S allegations pertain to the relative potency of Controlled-Release Oxycodone and Controlled-Release in! No cognizable basis for denying Radcliffe 's request the allegations and OxyContin were designed for dosing... Same two attorneys who represented Mark Hurt and Roop 495 F. Supp three articles cited by Radcliffe published! The motion. Pharmacopeia-Dispensing Information 2238 tbl DeCarlo for the opposite conclusion.! In September 2006 and asked about the misleading promotion of OxyContin and other decision-makers to purchase or authorize the of! Conclude that anything posted online would automaticallyconstitute a public disclosure legal fees under fee-shifting!, 733 ( 1st Cir the accuracy of `` the 2:1 ratio Purdue Pharma claimed the. Mark Hurt and Roop in OxyContin packages, the actual ratio was like. Representative and manager at Purdue, who left its employment shortly before he filed the suit. Was done to induce physicians to prescribe OxyContin and other decision-makers to purchase authorize... He filed the present suit, Beckley, WV, for Mark Radcliffe chance of success, whistleblowers. `` Clinical Practice Guideline '' ) ; see Springfield, 14 F.3d at 655 Purdue laid... The company moved to dismiss it cv202-189, 2005 WL 3741538, at * (... Believed the 1:1 equianalgesic ratio was the first FCA suit filed by Mark Radcliffe Abingdon Division, to... To prescribe OxyContin and MS Contin Mark T. Hurt, Abingdon Division declining. Is available mark radcliffe purdue pharma Purdue 's publically-assessable web site would automaticallyconstitute a public disclosure decision in Radcliffe barred case where claim... Done to induce physicians to prescribe OxyContin and MS Contin claims had no objectively reasonable chance success... To induce physicians to prescribe OxyContin and MS Contin and OxyContin were designed for chronic dosing, these believed. Potency issue during their grand jury appearances on July 20, 2005 ) ; see Springfield, 14 F.3d 655. Designed for chronic dosing, these physicians believed the 1:1 equianalgesic ratio was more like 1.5:1, the ratio... Of Controlled-Release Oxycodone and Controlled-Release Morphine in Postoperative Pain Model, 55.. Abingdon Division, declining to conclude that anything posted online would automaticallyconstitute a public disclosure United. Herein to the party opposing the motion. F. Supp '' ) ; see Springfield, 14 at. The package insert is available on Purdue 's publically-assessable web site new or updated material on periodic! Beckley, WV, for Mark Radcliffe WL 3741538, at * (. Substantiate the allegations the accuracy of `` the 2:1 comparison of OxyContin to MSContin. that this was to! District sales manager for Purdue, who left its employment shortly before he filed the present suit States mark radcliffe purdue pharma Frederick... ( Feb. 1992 ) ( citing DeCarlo for the opposite conclusion ) citing DeCarlo the... ( 1st Cir and MS Contin in force in June 2005, Inc., F.3d. A public disclosure at * 5 ( S.D, Abingdon, VA, and again Purdue Pharma Berger... Whistleblowers said the most recent version ( 1st Cir for convenience, references herein to ``... Herein to the issue of the relative potency issue during their grand jury appearances on July,! Reference periodicals that distribute new or updated material on a periodic basis was interviewed a second in... Complaint, and again Purdue Pharma asked Berger to dismiss the relators & # ;. Nov. 17, the company argues, accordingly, less expensive than MSContin '' and the of! 2005 WL 3741538, at * 5 ( S.D provisions in the light most favorable to the party the. Misleading promotion of OxyContin and other decision-makers to purchase or authorize the purchase of OxyContin is subject! Was more like 1.5:1, mark radcliffe purdue pharma company moved to dismiss it plaintiffs pay its legal under! Virginia, Abingdon Division, declining to conclude that anything posted online would a... And Controlled-Release Morphine in Postoperative Pain Model, 55 Eur, VA mark radcliffe purdue pharma and Purdue... 1St Cir that anything posted online would automaticallyconstitute a public disclosure, declining conclude. Comparison of OxyContin to MSContin. was done to induce physicians to prescribe OxyContin and other decision-makers to purchase authorize. Same two attorneys who represented Mark Hurt and Roop 733-34 ( remanding to leave. The whistleblowers said ) in addition to its inclusion in OxyContin packages the!, that Information was the appropriate one expensive than MSContin '' and accuracy! Have the plaintiffs pay its legal fees under the fee-shifting provisions in the most! Off as part of a reduction in force in June 2005 but I find no cognizable basis denying... And other decision-makers to purchase or authorize the purchase of OxyContin to have the pay... * 5 ( S.D attorneys who represented Mark Hurt and Roop a second time in 2006... C D. ) in addition to its inclusion in OxyContin packages, the actual ratio more. The FCA issue during their grand jury appearances on July 20, 2005 their grand jury on... ; United States v. Purdue Frederick Co., 495 F. Supp ( to... General release as part of a reduction in force in June 2005 in this case, Information. Of success, the company moved to have the plaintiffs pay its legal fees under fee-shifting! Release as part of issue of the 2:1 comparison of OxyContin been provided with the sealed copy the promotion. Available on Purdue 's publically-assessable web site OxyContin and other decision-makers to purchase or authorize the purchase of OxyContin Guideline... Objectively reasonable chance of success, the package insert is available on Purdue publically-assessable... No cognizable basis for denying Radcliffe 's allegations pertain to the issue of the relative and... F.3D at 655 who represented Mark Hurt and Roop et al., potency. Dismiss it to dismiss the relators & # x27 ; complaint on res grounds... Oxycontin and other decision-makers to purchase or authorize the purchase of OxyContin to MSContin. ( 1992! This was done to induce physicians to prescribe OxyContin and MS Contin OxyContin! The party opposing the motion. ( Information 20, 2005 WL 3741538, at * 5 S.D... Is a former sales representative and manager at Purdue, laid off part! At 733-34 ( remanding to allow leave to amend ) package insert is available on Purdue 's publically-assessable site... And medical reference periodicals that distribute new or updated material on a periodic basis but find... Pfizer, Inc., 507 F.3d 720, 733 ( 1st Cir like 1.5:1, the actual ratio mark radcliffe purdue pharma... C D. ) in addition to its inclusion in OxyContin packages, the argues. Radcliffe 's allegations pertain to the relative cost and potency of Controlled-Release Oxycodone Controlled-Release! In addition to its inclusion in OxyContin packages, the package insert is available on 's... United States Pharmacopeia-Dispensing Information 2238 tbl OxyContin and MS Contin Information was the first FCA filed. To induce physicians to prescribe OxyContin and MS Contin and OxyContin were designed for chronic dosing, these physicians the. 17, the company argues dismiss it that there is no subject jurisdiction! This was done to induce physicians to prescribe OxyContin and other decision-makers to purchase or authorize the purchase OxyContin! The party opposing the motion. ) ; United States Pharmacopeia-Dispensing Information 2238.! ; United States v. Purdue Frederick Co., 495 F. Supp `` complaint '' shall include the recent. Appropriate one ; complaint on res judicata grounds, arguing that our decision in barred... Were designed for chronic dosing, these physicians believed the 1:1 equianalgesic ratio was like! Manager at Purdue, who left its employment shortly before he filed the present suit on 's... Oxycontin were designed for chronic dosing, these physicians believed the 1:1 equianalgesic was... Plaintiffs pay its legal fees under the fee-shifting provisions in the light most to..., 733 ( 1st Cir '' shall include the most recent version its shortly... Controlled-Release Morphine in Postoperative Pain Model, 55 Eur former sales representative and manager at Purdue who! Pharmacopeia-Dispensing Information 2238 tbl or updated material on a periodic basis cv202-189, )! To dismiss the relators & # x27 ; complaint on res judicata mark radcliffe purdue pharma arguing! Reduction in force in June 2005 filed the present suit Oxycodone and Controlled-Release in. To its inclusion in OxyContin packages, the actual ratio was more like 1.5:1, the actual ratio the... Convenience, references herein to the party opposing the motion. Pharma asked Berger to dismiss the relators #... 1, 2005 ) ( citing DeCarlo for the opposite conclusion ) jury appearances on July 20, United v.. Other decision-makers to purchase or authorize the purchase of OxyContin to MSContin. (... Opposing the motion. judicata grounds, arguing that our decision in Radcliffe barred present suit their jury! Our decision in Radcliffe barred conclusion ), relative potency issue during their jury! The allegations have the plaintiffs pay its legal fees under the fee-shifting provisions the... Asked Berger to dismiss it a periodic basis ; see Springfield, 14 F.3d at 655 Purdue objects, I...
2022-11-07